company background image
CRNX

Crinetics Pharmaceuticals NasdaqGS:CRNX Stock Report

Last Price

US$18.59

Market Cap

US$999.3m

7D

-6.7%

1Y

-10.6%

Updated

27 Sep, 2022

Data

Company Financials +
CRNX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CRNX Stock Overview

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.

Crinetics Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Crinetics Pharmaceuticals
Historical stock prices
Current Share PriceUS$18.59
52 Week HighUS$28.95
52 Week LowUS$15.91
Beta1.2
1 Month Change-4.76%
3 Month Change3.28%
1 Year Change-10.63%
3 Year Change21.98%
5 Year Changen/a
Change since IPO-24.15%

Recent News & Updates

Sep 14
Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

CRNXUS BiotechsUS Market
7D-6.7%-3.3%-5.8%
1Y-10.6%-27.4%-22.1%

Return vs Industry: CRNX exceeded the US Biotechs industry which returned -30.6% over the past year.

Return vs Market: CRNX exceeded the US Market which returned -23.7% over the past year.

Price Volatility

Is CRNX's price volatile compared to industry and market?
CRNX volatility
CRNX Average Weekly Movement8.3%
Biotechs Industry Average Movement11.0%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: CRNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CRNX's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008143R. Struthershttps://www.crinetics.com

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases.

Crinetics Pharmaceuticals, Inc. Fundamentals Summary

How do Crinetics Pharmaceuticals's earnings and revenue compare to its market cap?
CRNX fundamental statistics
Market CapUS$999.26m
Earnings (TTM)-US$135.65m
Revenue (TTM)US$4.65m

215.0x

P/S Ratio

-7.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRNX income statement (TTM)
RevenueUS$4.65m
Cost of RevenueUS$84.26m
Gross Profit-US$79.61m
Other ExpensesUS$56.04m
Earnings-US$135.65m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.52
Gross Margin-1,712.72%
Net Profit Margin-2,918.40%
Debt/Equity Ratio0%

How did CRNX perform over the long term?

See historical performance and comparison